Product Information
ANORO ELLIPTA 62.5-25 MCG INH is a brand product labeled by GlaxoSmithKline LLC, priced at $8.0291 per EA under NDC 00173086906. Its NADAC has been published 409 times since Nov 21, 2018.
FDA first approved this application on Dec 18, 2013.
Strength
62.5; 25 ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173086906
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
9/23/2026
Active Ingredients
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA203975FDA Approved
12/18/2013
On Market Since
1/31/2014
Pharmacological Classes
Price Statistics
The NADAC for ANORO ELLIPTA 62.5-25 MCG INH has been published 409 times since Nov 21, 2018, and over the history we have for it it has risen 22.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.0291 per EA |
|---|---|
| All-time high | $8.0539 (Jun 11, 2025) |
| All-time low | $6.5501 (Nov 21, 2018) |
| 52-week high | $8.0452 |
| 52-week low | $8.0291 |
| Median price | $7.3720 |
| Average price | $7.4277 |
| Largest weekly change | +3.0% (Jan 9, 2019) |
| Weeks tracked | 409 |
| Tracking since | Nov 21, 2018 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 38% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
GlaxoSmithKline LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
umeclidinium bromide and vilanterol trifenatate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ANORO ELLIPTA 62.5-25 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for ANORO ELLIPTA 62.5-25 MCG INH, manufactured by GlaxoSmithKline LLC, is $8.0291 per EA (NDC 00173086906), effective Sep 30, 2026.
How has the price of ANORO ELLIPTA 62.5-25 MCG INH changed over time?
Over the history we have for it, the NADAC for ANORO ELLIPTA 62.5-25 MCG INH has risen 22.6%. It has been tracked across 409 weekly CMS publications since Nov 21, 2018.
What are the highest and lowest recorded NADAC prices for ANORO ELLIPTA 62.5-25 MCG INH?
Since Nov 21, 2018, the NADAC for ANORO ELLIPTA 62.5-25 MCG INH has ranged from a low of $6.5501 (Nov 21, 2018) to a high of $8.0539 (Jun 11, 2025), with a median of $7.3720 per EA.
Are there cheaper alternatives to ANORO ELLIPTA 62.5-25 MCG INH?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, UMECLIDINIUM-VILANTEROL ELLIPTA 62.5-25 MCG INH, is $4.9550 per EA — about 38% below ANORO ELLIPTA 62.5-25 MCG INH.
Who manufactures ANORO ELLIPTA 62.5-25 MCG INH?
ANORO ELLIPTA 62.5-25 MCG INH (NDC 00173086906) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.